![]() ![]() Without the investment in large equipment. We have seen significant increases in product yield.Īlso, the product can be scaled quite simply and easily It reduces the risk and provides, I think, a quick turnaround. The new process allows us to do it a lot safer. So, this new facility has been built to not only house the current requirements but then the projected requirements for five or ten years going forward. ![]() Scoresby allows us to design a purpose built facility for not only the current process but also for the new manufacturing process which we’ve designed with collaboration with the CSIROĪnd it also… I guess the footprint is a huge bonus for us as well. With the international markets coming on board we had to look at options to be able to support that increased capacityĪnd Scoresby was a site that we looked at very quickly. We’re looking to open up into 22 other countries in the next 12 months. It doesn’t have any side effects with regards to ability to be abused.Īnd we’ve also… looking at selling into parts of Europe, particular two countries are France and Belgium. It’s a non-opiate, so it’s a non-narcotic. It’s been used significantly in the ambulance services in Australia for many years for treating traumatic pain. There’s a lot of resources, a lot of equipment that would have to be brought into the four walls here at MDI to be able to support such a large research programme. Narrator: CSIRO have been a fantastic resource for MDI.īeing a small company we don’t often have the ability to invest in a lot of research and development. We have had some of the world’s best minds brought to us by the CSIRO all participating in the development of this new programme and we hope that that partnership will continue into the future. John Sharman: And without the CSIRO we wouldn’t be in the position today where we can have this really groundbreaking manufacturing process which allows us to go global. CSIRO, with all its’ capability with all its’ resource and expertise, can work closely with small companies to devise specific solutions for problems that are important for those companies business models. John Tsanaktsidis: To develop new processes to do R&D is costly and time consuming and small companies typically don’t have that resource, don’t have that flexibility. and our capacity to really improve our entire company we need to partner with the world’s best. John Sharman: The advantages of the new process that we’ve invented together with the CSIRO are that we, as a manufacturing outfit here in Springvale, can upscale our output by a factor of ten and have very significant cost reductions at the same time. has been to develop a better process, a process that can deliver a better quality product at a lower cost and a process that can deal with the needs of their growing market opportunity. John Tsanaktsidis: So the objective with this new interaction with M.D.I. We’ve been making it here for the last 15 years and together with the CSIRO over the last two and half three years we’ve invested almost $2 million on inventing a new way to manufacture Penthrox which will make us competitive on the world stage. The reality of an approval in Europe and elsewhere in the world means that Penthrox can fit a very significant market need in terms of getting people out of pain, getting them the proper treatment that they need without them having to take a narcotic on board. they’ll be able to use Penthrox.Īpproval in Europe for Penthrox really opens up the first global market for us in our history. If someone presents with trauma to a G.P. We’re used in the surf life saving arena. It is an inhaled analgesic which takes the pain away from people in trauma and we are frontline in ambulance. We make and distribute a drug called Penthrox which is our flagship product. John Sharman: Medical Developments is a listed public company. Together, we came up with a smart, efficient manufacturing process that significantly reduces the cost of producing Methoxyflurane while providing a more consistent result. In a technology deal, we invested $750,000 in order to significantly reduce the cost of producing Penthrox and facilitate large-scale production. Having developed the initial production process for Penthrox together, we've now vastly improved it. We have been working with MDI for more than 18 years. Our response Reducing costs and upscaling production With plans to export overseas, MDI needed a smarter, more efficient and cost-effective way to manufacture Methoxyflurane. It's non-addictive and simple to administer, making it an excellent choice for situations where fast-acting and uncomplicated relief is needed. Penthrox is an analgesic used by medical practitioners, the defence forces, ambulance paramedics, sports clubs and surf lifesavers to administer emergency pain relief. The pain-relieving drug Penthrox™ (commonly known as the green whistle).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |